- Anatomy -- Why are there so many CNS cell types? What properties define a cell type?
- Genetics -- Why do mutations in widely expressed genes that affect common biological pathways cause specific disorders? Why can so many genes cause CNS disorders?
- Therapy -- Can scientists develop circuit-specific drugs t
The Dementia Discovery Fund will pump $5 million in initial financing into Cerevance, a start-up developing new approaches to treating dementia patients, 60 percent of whom have Alzheimer’s disease. The venture capital fund invests in companies and projects pursuing disease-modifying therapies for dementia. Cerevance has dual headquarters in Boston and Cambridge, England. It is harnessing a proprietary technology platform that Dr. Nathaniel Heintz developed at the Howard Hughes Medical Institute in Chevy Chase, Maryland. The platform allows scientists to use human tissue samples, instead of animal models, to analyze human brain cells. The objective is to look at pathways and receptors in cell populations vulnerable to Alzheimer’s and other neurodegenerative diseases. Alzheimer’s is a research priority because it accounts for so much dementia. The World Alzheimer Report reports that a person who is 85 years old has a 50 percent chance of developing the disease, and the incidence is increasing. Cerevance is seeking to answer fundamental questions about the complexity of the central nervous system (CNS). The topics of research it is dealing with cover: